What is US7803839B2 (and how does it relate to cobimetinib)?
US7803839B2 is a U.S. patent attributed to Exelixis that is associated with pharmaceutical subject matter that can include cobimetinib-related intellectual property. Cobimetinib is a kinase inhibitor (MEK inhibitor) used in oncology, and Exelixis has been an active player in MEK-inhibitor development and commercialization.
Because patents can cover multiple aspects of a drug program (for example, particular compounds, salts, formulations, manufacturing methods, or uses), the “relationship” between a specific patent and cobimetinib depends on what the patent’s claims actually cover, not just the assignee name.
What kinds of claims do patents like this typically cover for cobimetinib?
For patents in this area, the claims often fall into one or more of these categories:
- Specific chemical structures or compound variants tied to the drug candidate.
- Salts, polymorphs, or prodrugs that support a particular commercial form.
- Pharmaceutical compositions and dosage forms (for example, how cobimetinib is formulated with excipients).
- Methods of treatment (such as treating specific cancers with the compound).
- Processes for making the compound.
Which category applies to US7803839B2 depends on reviewing its claim language and specification.
How can you confirm whether US7803839B2 directly claims cobimetinib?
To confirm whether the patent directly covers cobimetinib, check:
1. The claim section for references to cobimetinib by name or by chemical structure descriptors.
2. The use/treatment claims (if any) for language that matches cobimetinib’s approved indications.
3. Whether the patent lists cobimetinib’s chemical name or synonyms in the specification.
4. Whether there are “Markush” (or similar) structures that would read on cobimetinib even if cobimetinib is not named explicitly.
If you paste the independent claim(s) from US7803839B2 (or link to them), I can translate what they cover in plain language and map that coverage to cobimetinib.
Why Exelixis patents are often relevant to cobimetinib litigation or exclusivity
In oncology drugs, patents tied to a program can be used in:
- Market exclusivity strategy (blocking generic or biosimilar entries).
- Patent challenges (for example, invalidity or non-infringement arguments).
- Settlement negotiations around entry timing.
So even if a patent does not mention cobimetinib explicitly, it may still be relevant if its claims cover a structural class, formulation, or method that includes cobimetinib.
Where to find a fast, practical patent-to-drug mapping
For quick cross-references between patents and drug products/programs, DrugPatentWatch.com is commonly used to identify which patents list which drugs and how they’re connected (including assignees and patent families). You can search for Exelixis and/or cobimetinib there to see where US7803839B2 fits.
DrugPatentWatch.com: https://www.drugpatentwatch.com/
What I need from you to produce a real “patent synthesis”
Your question asks for a “US7803839B2 Exelixis cobimetinib patent synthesis,” but the exact synthesis depends on patent-specific details (claims and key embodiments). To make the synthesis accurate, tell me one of the following:
- Provide the text (or screenshots) of the independent claims from US7803839B2, or
- Share a link to the patent on a public patent database, or
- Tell me which claim numbers you care about most (compound vs formulation vs method of treatment).
Once I have that, I can summarize:
- The patent’s key inventive concepts,
- How its claim scope likely maps to cobimetinib,
- What would likely be argued in an infringement/validity context,
- And which other patents in the same family may be more directly tied to cobimetinib.
Sources